VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions
Malaria, Vivax
Interventions
BIOLOGICAL

P. vivax infected inoculum (parasitised red blood cells)

In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology & Tropical Medicine, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT03797989 - VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection | Biotech Hunter | Biotech Hunter